{"id":12022,"date":"2023-11-03T10:28:00","date_gmt":"2023-11-03T02:28:00","guid":{"rendered":"https:\/\/flcube.com\/?p=12022"},"modified":"2024-11-11T11:05:07","modified_gmt":"2024-11-11T03:05:07","slug":"eli-lilly-co-reports-36-yoy-sales-growth-in-q3-2023-with-key-drug-performances","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12022","title":{"rendered":"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances"},"content":{"rendered":"\n<p>Eli Lilly &amp; Co., (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) has announced its financial results for the third quarter of 2023, showing a 36% year-on-year (YOY) increase in sales to USD 9.5 billion in constant currency terms. This figure includes a USD 1.42 billion one-off payment from the sale of the Zyprexa (olanzapine) portfolio to Germany\u2019s Chelapharm, which was announced in April. Excluding this payment and COVID-19-related antibody sales from 2022, the underlying revenue growth for Q3\u201923 was 24% YOY.<\/p>\n\n\n\n<p><strong>Key Drug Performances<\/strong><br>Lilly&#8217;s standout performers were the CDK4\/6 breast cancer drug Verzenio (abemaciclib), which saw a 68% YOY increase to just over USD 1 billion, and the type 2 diabetes (T2D) and weight-loss drug Mounjaro (tirzepatide), with sales reaching USD 1.4 billion over the three months, USD 1.28 billion of which were earned in the United States. Diabetes medicine Jardiance (empagliflozin) grew by 22%, auto-immune disease drug Taltz (ixekizumab) by 9%, and while T2D drug Trulicity (dulaglutide) saw a 10% decrease in sales, it remained the leading product with over USD 1.6 billion in sales.<\/p>\n\n\n\n<p><strong>Pipeline Updates and Alzheimer\u2019s Therapy<\/strong><br>The most notable pipeline update was the adjustment to the expected US FDA regulatory decision timing for potential Alzheimer\u2019s therapy donanemab, which has been\u63a8\u8fdf from Q4\u201923 to Q1 2024.<\/p>\n\n\n\n<p><strong>China Market Growth<\/strong><br>China&#8217;s strong performance contributed to a 20% YOY increase in revenue in constant currency terms to USD 391 million over the three months. For the Q1-Q3 period, China sales have risen 12% YOY to USD 1.163 billion. Volume growth in the market was 25% YOY, partially offset by price declines. Key growth drivers were Verzenio and the programmed death-1 (PD-1) inhibitor Tyvyt (sintilimab), in partnership with Innovent Biologics, which saw a 50% YOY sales growth to USD 115.1 million. CFO Anat Ashkenazi commented, \u201cWe&#8217;re encouraged by the growth we have seen this year in China\u201d.<\/p>\n\n\n\n<p><strong>Regional Growth in 2023<\/strong><br>Lilly\u2019s regional growth during 2023 is as follows:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Q3 Sales (USD, mil.)<\/th><th>Q3 Growth*<\/th><th>YTD Sales (USD, mil.)<\/th><th>YTD Growth*<\/th><\/tr><\/thead><tbody><tr><td>US<\/td><td>5,368<\/td><td>21%<\/td><td>15,336<\/td><td>13%<\/td><\/tr><tr><td>Europe<\/td><td>2,569<\/td><td>136%<\/td><td>4,837<\/td><td>49%<\/td><\/tr><tr><td>Japan<\/td><td>391<\/td><td>-16%<\/td><td>1,234<\/td><td>-1%<\/td><\/tr><tr><td>China<\/td><td>391<\/td><td>20%<\/td><td>1,163<\/td><td>12%<\/td><\/tr><tr><td>Rest of World<\/td><td>780<\/td><td>23%<\/td><td>2,202<\/td><td>10%<\/td><\/tr><tr><td>Total<\/td><td>9,499<\/td><td>36%<\/td><td>24,771<\/td><td>18%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>*In constant currency terms<\/p>\n\n\n\n<p>Source: Lilly\u2019s Q3\u201923 earnings presentation<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly &amp; Co., (NYSE: LLY) has announced its financial results for the third quarter&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[16,39,199,27,911,18],"class_list":["post-12022","post","type-post","status-publish","format-standard","hentry","category-company","tag-cancer","tag-diabetes","tag-eli-lilly","tag-finanical-reports","tag-nyse-lly","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly &amp; Co., (NYSE: LLY) has announced its financial results for the third quarter of 2023, showing a 36% year-on-year (YOY) increase in sales to USD 9.5 billion in constant currency terms. This figure includes a USD 1.42 billion one-off payment from the sale of the Zyprexa (olanzapine) portfolio to Germany\u2019s Chelapharm, which was announced in April. Excluding this payment and COVID-19-related antibody sales from 2022, the underlying revenue growth for Q3\u201923 was 24% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12022\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12022\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-03T02:28:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-11T03:05:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12022#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12022\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances\",\"datePublished\":\"2023-11-03T02:28:00+00:00\",\"dateModified\":\"2024-11-11T03:05:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12022\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Diabetes\",\"Eli Lilly\",\"Finanical Reports\",\"NYSE: LLY\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12022#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12022\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12022\",\"name\":\"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-03T02:28:00+00:00\",\"dateModified\":\"2024-11-11T03:05:07+00:00\",\"description\":\"Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter of 2023, showing a 36% year-on-year (YOY) increase in sales to USD 9.5 billion in constant currency terms. This figure includes a USD 1.42 billion one-off payment from the sale of the Zyprexa (olanzapine) portfolio to Germany\u2019s Chelapharm, which was announced in April. Excluding this payment and COVID-19-related antibody sales from 2022, the underlying revenue growth for Q3\u201923 was 24% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12022#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12022\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12022#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter of 2023, showing a 36% year-on-year (YOY) increase in sales to USD 9.5 billion in constant currency terms. This figure includes a USD 1.42 billion one-off payment from the sale of the Zyprexa (olanzapine) portfolio to Germany\u2019s Chelapharm, which was announced in April. Excluding this payment and COVID-19-related antibody sales from 2022, the underlying revenue growth for Q3\u201923 was 24% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12022","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12022","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-03T02:28:00+00:00","article_modified_time":"2024-11-11T03:05:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12022#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12022"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances","datePublished":"2023-11-03T02:28:00+00:00","dateModified":"2024-11-11T03:05:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12022"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Diabetes","Eli Lilly","Finanical Reports","NYSE: LLY","PD-1\/L1"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12022#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12022","url":"https:\/\/flcube.com\/?p=12022","name":"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-03T02:28:00+00:00","dateModified":"2024-11-11T03:05:07+00:00","description":"Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter of 2023, showing a 36% year-on-year (YOY) increase in sales to USD 9.5 billion in constant currency terms. This figure includes a USD 1.42 billion one-off payment from the sale of the Zyprexa (olanzapine) portfolio to Germany\u2019s Chelapharm, which was announced in April. Excluding this payment and COVID-19-related antibody sales from 2022, the underlying revenue growth for Q3\u201923 was 24% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12022#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12022"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12022#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly &amp; Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12022"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12022\/revisions"}],"predecessor-version":[{"id":12023,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12022\/revisions\/12023"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}